Relation between number of prescribed medication and outcome in peritoneal dialysis patients

Clinical Nephrology

Volumn 66, Issue 4, 2006, Pages 256-262

  Szeto, C C ^a   Chow, K M ^a   Kwan, B C H ^a   Leung, C B ^a   Chung, K Y ^a   Law, M C ^a   Li, P K T ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardiovascular disease; Drug interaction; Renal failure

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM HYDROXIDE; ALUMINUM SALT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FUROSEMIDE; HYDRALAZINE; METHYLDOPA; NITRATE; VITAMIN D DERIVATIVE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HEART MUSCLE ISCHEMIA; HEMODIALYSIS PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; NUTRITIONAL ASSESSMENT; PERITONEAL DIALYSIS; POLYPHARMACY; PRESCRIPTION; RENAL OSTEODYSTROPHY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; UREMIA;

EID: 33749592177     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp66256     Document Type: Article

References (39)

1. Agarwal R. Hypertension and survival in chronic hemodialysis patients - past lessons and future opportunities. Kidney Int. 2005; 67: 1-13.
2. Ananth J, Parameswaran S, Gunatilake S. Antipsychotic polypharmacy. Curr Pharm Des. 2004; 10: 2231-2238.
3. Anderson RJ. Polypharmacy in the dialysis center. Int J Artif Organs. 1982; 5: 289-291.
4. Beddhu S, Zeidel ML, Saul M, Seddon P, Samore MH, Stoddard GJ, Bruns FJ. The effects of comorbid conditions on the outcomes of patients undergoing peritoneal dialysis. Am J Med. 2002; 112: 696-701.
5. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med. 1997; 157: 1531-1536.
6. Beers MH, Ouslander JG, Rollinger I et al. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med. 1991; 151: 1825-1832.
7. Bernardini J, Nagy M, Piraino B. Pattern of noncompliance with dialysis exchanges in peritoneal dialysis patients. Am J Kidney Dis. 2000; 35: 1104-1110.
8. Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1995; 6: 177-183.
9. Colley CA, Lucas LM. Polypharmacy: the cure becomes the disease. J Gen Intern Med. 1993; 8: 278-283.
10. Cox D. Regression models and life-tables. J R Stat Soc 1972; 34: 187-201.
11. Duranti E, Imperiali P, Sasdelli M. Is hypertension a mortality risk factor in dialysis? Kidney Int. 1996; 55 (Suppl): S173-S174.
12. First WH. Shattuck lecture: health care in the 21st century. N Engl J Med. 2005; 352: 267-272.
13. Gambassi G, Forman DE, Lapane KL et al. Management of heart failure among very old persons living in long-term care: has the voice of trials spread? Am Heart J. 2000; 139: 85-93.
14. Ganz DA, Lamas GA, Orav J et al. Age-related differences in management of heart disease: a study of cardiac medication use in an older cohort. J Am Geriatr Soc. 1999; 47: 145-150.
15. Giveon SM, Liberman N, Klang S, Kahan E. A survey of primary care physicians' perceptions of their patients' use of complementary medicine. Complement Ther Med. 2003; 11: 254-260.
16. Gurwitz JH. Polypharmacy: a new paradigm for quality drug therapy in the elderly? Arch Intern Med. 2004; 164: 1957-1959.
17. Gurwitz JH, Goldberg RJ, Chen Z et al. Beta-blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly. Am J Med. 1992; 93: 605-610.
18. Havranek EP, Abrams F, Stevens E et al. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch Intern Med. 1998; 158: 2024-2028.
19. Iseki K, Miyasato F, Tokuyama K, Nishime K, Uehara H, Shiohira Y, Sunagawa H, Yoshihara K, Yoshi S, Toma S, Kowatari T, Wake T, Oura T, Fukiyama K. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. Kidney Int. 1997; 51: 1212-1217.
20. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003; 63: 793-808.
21. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43 (Suppl 1): S1-S290.
22. Krumholz HM, Radford MJ, Wang Y et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction. JAMA. 1998; 280: 623-629.
23. McCormick D, Gurwitz JH, Goldberg RJ et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001; 161: 2458-2463.
24. McCullagh P, Nelder JA. Generalized linear models (2nd Ed.) London: Chapman and Hall; 1989.
25. McLaughlin TJ, Soumerai SB, Willison DJ et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med. 1996; 156: 799-805.
26. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42 (Suppl 3): S1-S201.
27. NKF-K/DOQI Clinical practice guidelines for peritoneal dialysis adequacy: Update 2000. Am J Kidney Dis. 2001; 37 (Suppl 1): S65-S136.
28. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353: 487-497.
29. Piraino B, Bernardini J. The problem of compliance with PD exchanges. Semin Dial. 2000; 13: 160-162.
30. Port FK, Wolfe RA, Bloembergen WE, Held PJ, Young EW. The study of outcomes for CAPD versus hemodialysis patients. Perit Dial Int. 1996; 16.: 628-633.
31. Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA, Agodoa LY, Young EW. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999; 33: 507-517.
32. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol. 2003; 14 (Suppl 4): S315-S320.
33. Rochon PA, Gurwitz JH. Prescribing for seniors: neither too much nor too little. JAMA. 1999; 282: 113-115.
34. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit 1990 to 2002. J Am Coll Carcliol. 2003; 41: 56-61.
35. Sueta CA, Chowdhury M, Boccuzzi SJ et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999; 83: 1303-1307.
36. Szeto CC, Wong TY, Chow KM, Leung CB, Li PK. Are peritoneal dialysis patients with and without residual renal function equivalent for survival study? Insight from a retrospective review of the cause of death. Nephrol Dial Transplant. 2003; 18: 977-982.
37. Szeto CC, Wong TY, Leung CB, Wang AY, Law MC, Lui SF, Li PK. Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney Int. 2000; 58: 400-407.
38. Wilder BJ, Homan RW. Definition of rational antiepileptic polypharmacy. Epilepsy Res. 1996; 11 (Suppl): 253-258.
39. Zager PG, Nikolic J, Brown PH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P. "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic Inc. Kidney Int. 1998; 54: 561-569.